Generally, TLR agonists are very promising for tumour immune therapy.97 Preclinical and phase 1 clinical trial results of a TLR7 agonist have been identified with induction of type I IFN responses in HER2+ solid tumour patients (NCT03696771).98 In addition, TLR7/8 agonist has been attempted to use combined with ICB and enhances immunity response in TME.99–101. The gene discussed is TLR7; the disease is neoplasm.